AbbVie Inc. (ABBV) News
Filter ABBV News Items
ABBV News Results
|Loading, please wait...|
ABBV News Highlights
- For ABBV, its 30 day story count is now at 151.
- Over the past 29 days, ABBV's stories per day has been in a clear downtrend, falling by about -0.58 per 1 days.
- The most mentioned tickers in articles about ABBV are ROKU, CMI and INFO.
Latest ABBV News From Around the Web
Below are the latest news stories about AbbVie Inc that investors may wish to consider to help them evaluate ABBV as an investment opportunity.
For instance, the S&P 500's cyclically adjusted price-to-earnings ratio -- a measure of the stock market's valuation -- is currently 36.6, the highest it has been in more than 10 years. Right now, two such companies are AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie currently trades for just 8.7 times forward earnings, while its price-to-earnings growth ratio (PEG) is 0.19.
The U.S. Food and Drug Administration (FDA) has now pushed back two reviews for regulatory filings by AbbVie (NYSE: ABBV) for Rinvoq. This autoimmune disease drug is an important component of the company's growth strategy. In this Motley Fool Live video, recorded on April 7, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie and its shareholders should be worried about Rinvoq.
Photo by efetova/iStock via Getty ImagesThis year started with picking three dividend-income investing stocks that scored an A+ in one or more Seeking Alpha Premium ratings. AbbVie (ABBV), AT&T (T), and Altria (MO) each had unique attributes for readers to pick. Only one of the picks performed the best so...
Foreword As supplement to this article, please note that Kiplinger has published an on-line slide-show detailing the latest 2021 65 S&P Dividend Aristocrats. The article entitled 65 Best Dividend Stocks You Can Count On in 2021, is by Dan Burrows a contributing editor. While more than half this collection of...
Top Research Reports for Home Depot, Toyota & IBM
AbbVie (ABBV) closed at $108.22 in the latest trading session, marking a -0.03% move from the prior day.
Taking It Easy Before Earnings
The FDA extended the review for AbbVie's (NYSE: ABBV) Rinvoq as a treatment for psoriatic arthritis. Brian Orelli: So, last week, AbbVie said that the FDA is extending its review of Rinvoq as a treatment for psoriatic arthritis.
Investors approaching retirement tend to be focused on investing prudently in those last few years before leaving the workforce, with many seeking to maximize their dividend income. AbbVie came on to the market in 2013 after being spun off from medical device company Abbott Labs. It joined a crowded landscape, competing against the likes of Johnson & Johnson, Pfizer, Merck, and Bristol Myers Squibb.
Stocks Analysis by Zacks Investment Research covering: AbbVie Inc. Read Zacks Investment Research's latest article on Investing.com